SharesGrow.com Intrinsic Value of S&P & Nasdaq Contact Us

हिन्दी

← Back to all stocks

Fresh Tracks Therapeutics, Inc. FRTX NASDAQ

NASDAQ Capital Marke • Healthcare • Biotechnology • US • USD

SharesGrow Score

SharesGrow Intrinsic Value

Negative cash flow

Fresh Tracks Therapeutics, Inc. (FRTX) is a Biotechnology company in the Healthcare sector, currently trading at $0.94. It has a SharesGrow Score of 51/100, indicating a mixed investment profile with 2 out of 7 criteria passed.

Financials: revenue is $8M, +518.7%/yr average growth. Net income is $6M (loss), growing at +10.4%/yr. Net profit margin is -71.1% (negative). Gross margin is 100% (+615.6 pp trend).

Balance sheet: total debt is $0 against $10M equity (Debt-to-Equity (D/E) ratio 0, conservative). Current ratio is 6.98 (strong liquidity). Debt-to-assets is 0%. Total assets: $12M.

Analyst outlook: 1 / 1 analysts rate FRTX as buy (100%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 90/100 (Pass), Past 0/100 (Fail), Health 67/100 (Partial), Moat 50/100 (Partial), Future 100/100 (Pass), Income 10/100 (Fail).

FRTX SharesGrow Score Overview

63/100

SharesGrow Score

Above average fundamentals

View full scorecard →

VALUE 0/100

Valuation — P/E, PEG, Forward PEG

GROWTH 90/100

Financials — average growth

PAST 0/100

strong — trend

HEALTH 67/100

Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is

MOAT 50/100

Gross margin is + market cap

FUTURE 100/100

Analyst outlook — as buy

INCOME 10/100

Net profit margin is

Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — FRTX

No analyst coverage available for this stock.

FRTX: +518.7%/yr revenue is, +10.4%/yr Net income is average growth. > 5%/yr — strong. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.

View details →

No analyst coverage available for this stock.

Balance sheet FRTX: Debt-to-Equity (D/E) ratio 0 (conservative), Current ratio is 6.98 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.

View details →

FRTX: Gross margin is 100% (+615.6 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 50/100. ≥ 70 = Pass.

View details →

Analyst outlook: 1 / 1 analysts rate FRTX as buy (100%). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.

View details →

FRTX: Net profit margin is -71.1%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.

View details →

Stock Chart & Stats

Market Data

52-Week Range0.03-1.0325

Volume2.16K

Avg Volume (30D)2.67K

Market Cap$5.59M

Beta (1Y)1.17

Share Statistics

EPS (TTM)-0.96

Shares Outstanding$5.91M

IPO Date1993-03-10

Employees4

CEOAlbert Nicholas Marchio II

Financial Highlights & Ratios

Revenue (TTM)$8.01M

Gross Profit$8.01M

EBITDA$-5.65M

Net Income$-5.69M

Operating Income$-6.36M

Total Cash$10.87M

Net Debt$-10.87M

Total Assets$11.59M

Price / Earnings (P/E)-1

Price / Sales (P/S)0.7

Analyst Forecast

Rating ConsensusBuy

Analysts Covering1

Buy 100% Hold 0% Sell 0%

Company Info

CountryUS

ExchangeNASDAQ Capital Marke

CurrencyUSD

ISINUS10802T2042

Price Chart

FRTX

Fresh Tracks Therapeutics, Inc. ↗ · NASDAQ Capital Marke

Healthcare • Biotechnology

0.03 52WK RANGE 1.03

People Also View

Nuvation Bio Inc.

Assembly Biosciences, Inc.

Third Harmonic Bio, Inc.

Unicycive Therapeutics, Inc.

Achilles Therapeutics plc

Instil Bio, Inc.

SAB Biotherapeutics, Inc.

Contact Us

🎓

SharesGrow Academy

Learn how to calculate Intrinsic Value and find undervalued stocks.

Weekly live sessions

📧 [email protected]

📞 +65 8912 8000

Send us a message